Evidence map›Paper›PMID 42394492›Full record

ArticleZhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences2026

[Untargeted metabolomics-based exploration of potential metabolic biomarkers for subclinical atherosclerosis in metabolic-associated fatty liver disease].

Yaqin Wang, Ting Yuan, Lei Liu, Zhuolin Su, Linlin Wan, Changfa Wang, Xiaoling Zhu, Zhongyang Hu

Abstract readEnglish Abstract
PubMed Full text at PMC Publisher
In one paragraph

Article in Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Yaqin WangHealth Management Medical Center, Third Xiangya Hospital, Central South University, Changsha 410013. wangy11@csu.edu.cn.
Ting YuanHealth Management Medical Center, Third Xiangya Hospital, Central South University, Changsha 410013. 50279224@qq.com.
Lei LiuHealth Management Medical Center, Third Xiangya Hospital, Central South University, Changsha 410013.
Zhuolin SuDepartment of Neurology, Third Xiangya Hospital, Central South University, Changsha 410013.
Linlin WanDepartment of Radiology, Xiangya Hospital, Central South University, Changsha 410008.
Changfa WangDepartment of Hepatobiliary Surgery, Third Xiangya Hospital, Central South University, Changsha 410013, China.
Xiaoling ZhuHealth Management Medical Center, Third Xiangya Hospital, Central South University, Changsha 410013.
Zhongyang HuDepartment of Neurology, Third Xiangya Hospital, Central South University, Changsha 410013. zhongyanghu@163.com.

Funding

the Natural Science Foundation of Changsha kq2403048 and kq2208351
6 · The paper itself

Abstract

objectivesCardiovascular disease is the most common extrahepatic complication and leading cause of death in metabolic dysfunction‑associated fatty liver disease (MAFLD). However, early metabolic biomarkers for subclinical atherosclerosis (SA) in MAFLD patients remain unclear. This study used untargeted metabolomics to investigate serum metabolite and pathway changes associated with SA in MAFLD patients and to screen for potential serum metabolic biomarkers.

methodsFrom December 2023 to December 2024, 64 MAFLD patients with SA enrolled in the "Pan-Vascular Cohort Study" at the Health Management Medical Center of the Third Xiangya Hospital of Central South University were included as an experimental group, and 50 age- and sex-matched MAFLD patients without SA were included as controls. MAFLD was diagnosed according to the

resultsUsing selection criteria of FDR-corrected

conclusionsThe metabolic profiles of MAFLD patients with and without SA differ significantly. Key differential metabolites may serve as potential biomarkers for predicting atherosclerosis in MAFLD patients.

Indexed as

AtherosclerosisMetabolomicsNon-alcoholic Fatty Liver DiseaseBiomarkersFemaleHumansLysophosphatidylcholinesMaleMiddle AgedBiomarkersLysophosphatidylcholinesbiomarkerlysophosphatidylcholinemetabolic dysfunction‑associated fatty liver diseasemetabolomicssubclinical atherosclerosis

Identifiers

PMID42394492
PMCPMC13305680

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.